The interactions between Plasmodium parasites and human erythrocytes are prime targets of 25 blood stage malaria vaccine development. The reticulocyte binding protein 2-P1 (RBP2-P1) of 26 Plasmodium vivax, a member of the reticulocyte binding protein family, has recently been shown 27 to be highly antigenic in several malaria endemic settings. Yet, its functional characteristics and 28 the relevance of its antibody response in human malaria have not been examined. In this study, 29 the potential function of RBP2-P1 as an invasion ligand of P. vivax was evaluated. The protein 30 was found to be expressed in schizonts, be localized at the apical end of the merozoite, and 31 preferentially bind reticulocytes over normocytes. Human antibodies to this protein also exhibit 32 erythrocyte-binding inhibition at physiologically relevant concentration. Furthermore, RBP2-P1 33 antibodies are associated with lower parasitemia and tend to be higher in asymptomatic carriers 34 than patients. This study provides evidence supporting a role of RBP2-P1 as an invasion ligand 35 and its consideration as a vaccine target. 36 37 Keywords. vivax malaria; reticulocyte binding protein 2-P1; binding; immunity; invasion 38 (157 words) 39 on March 7, 2020 by guest http://iai.asm.org/ Downloaded from Introduction 40 Plasmodium vivax is the major cause of malaria outside Africa (1). All clinical manifestations of 41 malaria are associated with the blood-stage infection, during which erythrocytes are invaded by 42 the parasite. Unlike P. falciparum, P. vivax specifically infects young erythrocytes 43 (reticulocytes). This restricted host cell tropism is mediated by the interaction between parasite 44 ligands and host cell receptors. Two key families of P. vivax invasion ligands are the Duffy 45 Binding Protein (DBP) family and the Reticulocyte Binding Protein (RBP) family. Cumulative 46 evidence has strongly implicated a role of the members of the RBP family in reticulocyte 47
selection (2-4), but proteins in the DBP family may also contribute to the host selection (5, 6) . 48
49
The DBP family consists of two proteins, DBP and Erythrocyte Binding Protein (EBP). These 50 proteins are homologs of the P. falciparum Erythrocyte Binding antigens (EBAs). DBP binds the 51 Duffy Antigen Receptor for Chemokines (DARC), is nearly essential for P. vivax invasion of 52 reticulocytes (7, 8) , and is the most advanced candidate for vaccine against blood-stage P. vivax. 53 EBP, on the other hand, was recently discovered (9) . A recent functional study demonstrated that 54 this protein preferentially binds Duffy-positive reticulocytes (5). The RBP family was originally 55 discovered in 1980s, when Galinski and coworkers searched for reticulocyte-specific invasion 56 ligands (10) . Two members of the family (RBP1a and RBP2c) were discovered then. Other 57 family members (RBP1b, RBP2a, RBP2b, RBP2-P1, and RBP2-P2) were identified when the 58 whole genome sequence became available, along with three pseudogenes (RBP2d, RBP2e, and 59 RBP3) (9, 11) . Most RBPs (RBP1a, RBP1b, RBP2a, RBP2b, RBP2c, and RBP2-P2) were 60 recently characterized and found to have erythrocyte binding capacity and varying degrees of 61 reticulocyte selectivity (3, 4, (12) (13) (14) . Human antibodies to some of these proteins are associated 62 on March 7, 2020 by guest http://iai.asm.org/ Downloaded from 4 with reduced parasitemia (15) or protection against clinical disease (13) . Notably, RBP2b has 63 been shown to bind reticulocytes specifically through interaction with transferrin receptor 1 64 (TfR1), a surface protein abundant on the surface of reticulocytes but nearly absent from 65 normocytes (4). The interaction between RBP2b and TfR1 was highly important for invasion; 66 TfR1 deficient reticulocytes are highly refractory to P. vivax invasion. 67
68
The remaining uncharacterized P. vivax invasion ligand of the RBP family was RBP2-P1. With 69 622 amino acids, RBP2-P1 is a truncated member of the family and is approximately 4-5 folds 70 smaller than the full-length RBPs. Interestingly, RBP2-P1 is composed primarily of the 71 erythrocyte binding domain, very much like RH5 protein of P. falciparum. In this study, we 72 examined the function of RBP2-P1 and its antibody response in malaria patients and 73 asymptomatic carriers. 74 75
Results

76
The 622 amino acid long RBP2-P1 has a predicted signal peptide (residues Met1-Cys21). Much 77 of the sequence spans the N-terminal binding domain which is conserved among the reticulocyte 78 binding protein family of Plasmodium (Fig. 1A) . Sequence alignment (see in the Supplemental 79 Material) of RBP2-P1 from 7 isolates (Sal-1, Thai, Mauritania, Brazil, India, Korea, and 80 PVP01_0534400) reveals cysteines at positions known to form the disulfide bridges in some 81 RBPs (12) (Fig. 1A, 1B) . 82 83 Expression and purification of RBP2-P1 84 on March 7, 2020 by guest http://iai.asm.org/ Downloaded from 5 The recombinant RBP2-P1 (rRBP2-P1) was successfully expressed in E. coli. The purified 85 protein with the 6-His tag had an expected size of 73 kDa, consistent with the predicted 86 molecular size of rRBP2-P1 (see Fig. S2 in the supplemental material). After removal of the 6-87
His tag, the final protein had the predicted size of 70 kDa and migrated as a single peak on gel 88 filtration (Fig. 1C ). Circular dichroism spectroscopy ( Fig. 1D ) suggests that the protein was well 89 folded and composed mainly of alpha helices, as expected from the crystal structures of related 90 proteins (4, 12, 17) . 91 92 RBP2-P1 is expressed in the parasite. 93
Polyclonal antibodies against the rRBP2-P1 were raised in rabbits and showed reactivity with the 94 rRBP2-P1 in immunoblots as compared to no reactivity from the pre-immune sera ( Fig. 2A) . 95
Western blot analysis performed on P. vivax lysate using the rabbit antisera confirmed RBP2-P1 96 expression in the parasite. Two protein bands were detected, with the upper band having the 97 same gel mobility as rRBP2-P1. The presence of two bands suggests proteolytic processing of 98 the RBP2-P1 protein, as commonly observed for parasite proteins (18, 19) (Fig. 2B ). The 99 specificity of the rabbit antisera was further tested against six additional rRBPs. The results 100 confirmed that the rabbit antisera did not cross-react with other rRBPs (Fig. 2C) . 101 102 RBP2-P1 is localized at the epical ends of merozoites. 103
Microarray analyses of blood-stage P. vivax detected peak RBP2-P1 transcript abundance at the 104 late schizont stage (20, 21) . To determine the localization of RBP2-P1 in schizonts, IFA was 105 performed on schizonts enriched from patient's blood (Fig. 3) . The rabbit immune serum and 106 anti-RBP2-P1 IgG recognized endogenous RBP2-P1 in infected RBCs. The fluorescent signals 107 on March 7, 2020 by guest http://iai.asm.org/ Downloaded from 6 overlapped with those of DBP, a micronemal protein, suggesting apical localization of RBP2-P1. 108
Interestingly, the expression of RBP2-P1 was found only in late schizonts (8 nuclei or more), 109 unlike DBP which could already be detected in early schizonts (Fig. 3A, 3D) . 110
111
RBP2-P1 preferentially binds reticulocytes over normocytes. 112
Binding characteristic of rRBP2-P1 was determined with enriched reticulocytes using a flow 113 cytometry-based erythrocyte-binding assay (Fig. 4A ). The results showed that rRBP2-P1 bound 114 reticulocytes over normocytes with statistically significant difference (Fig. 4B ). The effect of 115 enzyme treatment to erythrocytes on rRBP2-P1 binding was investigated by erythrocyte 116 enzymatic treatments prior to the conventional erythrocyte binding assay (Fig. 4C ). The binding 117 activity of rRBP2-P1 was reduced when erythrocytes were pre-treated with trypsin and 118 chymotrypsin but not with neuraminidase ( Fig. 4D ). It is noted that while trypsin treatment 119 generally reduced binding of rRBP2-P1, the binding to Donor 5's cells appeared unaffected by 120 trypsin. The reason for this is unclear, but it is possible that the erythrocyte receptor may carry 121 one or more mutations that rendered the protein resistant to the enzyme. 122 123 Erythrocyte binding of RBP2-P1 is blocked by antibodies. 124
We next investigated whether antibodies could interfere with rRBP2-P1 binding to erythrocytes. 125
When rabbit anti-rRBP2-P1 IgG was incubated with rRBP2-P1 (5 g/ml), binding of the rRBP2-126 P1 to erythrocytes was reduced in a dose-dependent manner with an IC50 value of 90 g/ml 127 were villagers who were P. vivax positive at multiple times (3-13) out of the 14 monthly visits 135 but never developed any malaria-like symptoms. Naïve individuals were people from the same 136 study area who were not infected during the study period and reported not to have had malaria 137 before. The general characteristics of the study participants are provided in Table 1 . The level of 138 RBP2-P1 antibodies in patients and asymptomatic carriers was negatively correlated with 139 parasitemia (P = 0.007, Spearman's rank correlation) ( Fig. 6A ). This relationship remains 140 statistically significant after age has been taken into account (P < 0.01, multivariate linear 141 regression). Consistently, asymptomatic carriers tend to have higher antibody levels than patients 142 with parasitemia above 0.1% ( In agreement with the observation that P. vivax malaria patients had higher IgG levels against 146 rRBP2-P1 than did naïve individuals, immunoblots showed that patient serum, but not naïve 147 serum, reacted with the rRBP2-P1 protein ( Fig. 7C ). To test whether human antibodies could 148 inhibit erythrocyte binding of rRBP2-P1, we affinity-purified immunoglobulins recognizing 149 rRBP2-P1 from pooled plasma from ten vivax patients and used them in the binding inhibition 150 assay. Similar to the rabbit anti-rRBP2-P1 IgG, the purified human antibodies could inhibit the 151 binding with an IC50 value of 135 g/ml ( Fig. 7A, 7B ), a level that can be attained in some 152 human patient plasma ( RBP2-P1 was discovered when the first P. vivax genome was sequenced (11). Interestingly, 156 RBP2-P1 was first annotated as a pseudogene, perhaps reflecting its unusual structural 157 architecture containing only the N-terminal binding domain. Among the RBPs, only RBP2-P1 158 and RBP2-P2 have this truncated structure, which is shared by PfRH5, an essential invasion 159 ligand of P. falciparum which interacts with human basigin on the surface of erythrocytes. 160
Whereas RBP-2P2 is absent in some isolates, RBP2-P1 is found in all P. vivax isolates (11, 15, 161 23) as well as in P. cynomolgi (24). These observations together suggest the importance of 162 RBP2-P1. Until now, RBP2-P1 has remained the only P. vivax RBP that has not been 163 functionally examined. 164
165
We successfully expressed full-length rRBP2-P1 and characterized its binding to erythrocytes. 166
Like several RBPs (3, 13, 14) , the protein preferentially binds reticulocytes over normocytes. 167
Binding to erythrocytes was sensitive to trypsin and chymotrypsin treatments, but insensitive to 168 neuraminidase treatment. This sensitivity profile differs from that of PfRH5, suggesting that 169 RBP2-P1 may not bind basigin. In contrast, the enzyme sensitivity profile of rRBP2-P1-170 erythrocyte interaction was similar to that of PfRH4 which binds the human complement 171 receptor 1 (CR1) (25) and RBP2b which binds human transferrin receptor 1 (TfR1) (4). The 172 erythrocyte receptor of RBP2-P1 is currently not known. It is also unclear whether this protein 173 functions as one of the alternate invasion pathways among the RBPs. However, the fact that it 174 has a distinct structure -being the smallest and composed only of the N-terminal domain -175
suggests that it has a unique function. 176 on March 7, 2020 by guest http://iai.asm.org/ Downloaded from 9 177 Natural infection of P. vivax has recently been shown to induce strong antibody response to 178 RBP2-P1 (26). In the current study, the levels of human antibody to RBP2-P1 were measured in 179 both P. vivax patients and carriers. Higher responses were associated with lower parasite 180 densities. Consistently, the levels of anti-rRBP2-P1 antibodies are generally higher in 181 asymptomatic carriers than in patients, a trend shared by several blood stage vaccine targets 182
including PfEBAs, PfMSPs, and PfRHs (27, 28) . Although the association may reflect past 183 exposure, that human antibodies interfere with RBP2-P1 erythrocyte binding suggests that these 184 antibodies could contribute to protection by inhibiting erythrocyte invasion. An invasion 185 blocking experiment will be required to test this possibility. It is also possible that RBP2-P1 186 antibodies provide clinical protection through a different mechanism such as complement 187 fixation (29) . 
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Scientific) in the blocking buffer overnight at 4°C. After membrane washes with PBST, the 246 membrane was incubated with the goat anti-mouse HRP (1:5,000 dilution) (Millipore) in the 247 blocking buffer for 1 hr at RT. The membrane was washed and the HRP activity was detected 248 with 3,3',5,5'-Tetramethylbenzidine reagent (Millipore). To determine the reactivity of patient 249 serum, rRBP2-P1 (without 6-His tag) was probed with patient serum (1:250 dilution) and 250 incubated with the goat anti-human HRP (1:5,000 dilution) (Millipore). The reactivity of rabbit 251 immune serum to the parasite protein was determined with parasite lysate. ∼3x10 9 cells of P 252 vivax infected RBC were scrapped from thin film blood smears and added 4x reducing sample 253 loading buffer. The membrane containing parasite protein was probed with rabbit immune serum 254
(1:1,000 dilution) and then incubated with the goat anti-rabbit HRP (1:5,000 dilution) 255 (Millipore). 256 257
Antibody Production 258
Antibodies against rRBP2-P1 were produced by Thermo Fisher Scientific (USA). Briefly, two 259 rabbits were immunized intramuscularly with 0.50 mg of rRBP2-P1 emulsified with Freund's 260 complete adjuvant on day 0, followed by three boosts of the antigen emulsified with incomplete 261
Freund's adjuvant on days 14, 42 and 56. The serum was collected on day 70. Serum was also 262 used for rabbit IgG purification by Protein G Sepharose (GE Healthcare) according to the 263 standard protocol. Specificity of serum for rRBP2-P1 was confirmed by Western blot analysis 264 against recombinant P. vivax RBPs (rRBPs) (13). For this, 1 ng of each rRBPs were separated on 265 SDS-PAGE and transferred to the membrane. The membrane containing proteins was probed 266 with rabbit anti-rRBP2-P1 IgG (1 μg/ml) following with goat anti-rabbit HRP (0.2 μg/ml) 267 For affinity purification of human antibodies, rRBP2-P1 (10 mg) was coupled to 1 ml packed 285 CNBR activated Sepharose (GE Healthcare) according to the manufacturer's instruction. 10 ml 286 of serum samples pooled from ten P. vivax malaria patients were used for antibody purification. 287
The pooled sera were centrifuged to remove insoluble particles before incubating with the 288 rRBP2-P1-coupled resins for 1 hr at room temperature (RT). The unbound materials were 289 
Reticulocyte Enrichment 294
Reticulocytes were enriched from whole blood from The Thai Red Cross Society. Blood was 295 passed through leukocyte reduction filter (Haemonetics Corporation) and centrifuged at 1,000g 296 for 10 min to discard the plasma. The packed cells were mixed with 2 volumes of incomplete 297 RPMI-1640 medium and centrifuged at 1,000g for 10 min. The packed cells were diluted to 298 20% hematocrit. Then, 4 ml of the diluted blood were gently layered on top of 4 ml of 15% 299
Optiprep-KCl (Axis-Shield) and centrifuged at 3,000g for 30 min without braking. 300
Reticulocytes were collected at the interface and washed 3 times with incomplete RPMI-1640 301 medium and kept at 4°C. 302 303
Flow Cytometry Erythrocyte Binding Assay 304
A flow cytometry-based quantitative erythrocyte binding assay was performed as follows. First, 305 enriched reticulocyte fraction was washed three times with PBS and incubated in the blocking 306 solution (1% BSA in PBS containing 0.6 mM CaCl 2 ) at room temperature for 1:30 hr. After 307 centrifugation and removal of blocking solution, 100 l of rRBP2-P1 solution (5 g in PBS + 0.6 308 mM CaCl 2 ) or control solution (PBS + 0.6 mM CaCl 2 ) was added to 1x10 7 cells and incubated at 309 room temperature. After 1:30 hr incubation, cells were centrifuged and the supernatant was 310 removed. Rabbit anti-RBP2-P1 IgG (10 g in 200 l blocking solution) was added to the cells. Retic-Count Reagent, BD Biosciences) supplemented with 0.6 mM CaCl 2 was added. The cell 316 suspension was incubated at room temperature for 30 min in the dark and 500,000 erythrocytes 317 were read and analyzed on Accuri C6 flow cytometer (BD Bioscience). 318 319
Conventional Erythrocyte Binding Assay 320
The conventional erythrocyte binding assay was performed using standard procedure (16). 321
Briefly, 100 µl erythrocytes were washed three times with PBS and the resulting packed cells 322 were mixed with 100 l PBS containing rRBP2-P1 (0.5 g for protein without 6-His tag, or 10 323 g for protein with 6-His tag) and incubated for 1.5 hr at RT. The cell suspension was then 324 centrifuged through 500 l dibutyl phthalate (Sigma) at 12,000g for 30 sec. The supernatant 325 and oil were removed and the packed cells were centrifuged once again through dibutyl 326 phthalate. Bound protein was eluted from packed erythrocytes with 50 l of 1.5 M NaCl. The 327 presence of recombinant protein in the eluate was determined by Western blot using rabbit anti-328 RBP2-P1 IgG or anti-His tag antibody as the primary antibodies, followed by appropriate 329 horseradish peroxidase (HRP) conjugated secondary antibodies for chemiluminescent detection 330 using Immobilon Western substrates (Millipore) and detected with the GeneSys image capture 331 software (G:BOX Chemi XRQ Syngene). The densitometry analysis was performed with the 332 ImageQuant TM TL software (GE healthcare). 333 334 For enzymatic treatment, erythrocytes at 10% hematocrit in PBS were treated with 66 mU/ml 335 neuraminidase (Sigma), or trypsin/chymotrypsin (Sigma) at 0.2 and 2 mg/ml as low and high 336 on March 7, 2020 by guest http://iai.asm.org/ Downloaded from 16 enzymatic treatment respectively, at 37°C for 1 hr. The treated cells were washed once with 10 337 volumes of PBS and incubated with 10 volumes of 2 mM PMSF in PBS at RT for 15 min. After 338 three washes with 10 volume of PBS, the treated cells were used immediately in erythrocyte 339 binding assays. 340
341
To determine whether RBP2-P1 antibodies could block in vitro binding of the RBP2-P1 protein 342 to erythrocytes, rRBP2-P1 (without 6-His tag, 0.5 g) was mixed with 3. 8, 7.5, 11.3, 15.0, 18.8, 343 and 22.6 µg of rabbit anti-RBP2-P1 IgG or 3. 8, 7.6, 11.4, 15.2, 19.0, 22.8 and 26.6 µg human 344 anti-RBP2-P1 antibodies in a final volume of 100 µl. The mixture was incubated for 1 hr at RT 345 and transferred into 100 µl packed erythrocytes. Binding of rRBP2-P1 to erythrocytes was 346 determined as described above. The presence of bound protein was determined by Western blot 347 using HRP-conjugated rabbit anti-RBP2-P1 IgG for direct chemiluminescent detection and 348 quantified by densitometry. The dose response curves (Fig. 5, 7) were fitted with a Hill's 349 equation for binding of rRBP2-P1 to erythrocytes, assuming that rRBP2-P1 free concentration is 350 reduced linearly by the increasing concentration of antibodies. carriers were compared using the Mann-Whitney Rank Sum test. Sex, age, and the RBP2-P1 375 antibody level were examined as potential factors underlying parasitemia. Only the antibody 376 level was found to be a significant determinant of parasitemia in univariate analysis (P = 0.004 in 377 linear correlation and 0.007 in rank correlation). The relationship between the antibody level and 378 parasitemia remained significant (P = 0.003) when all three variables (sex, age, and antibody 379 level) were included in a multivariate linear-regression model. Raw data used in these analyses 380 are provided in Supplemental Table S1 
